The effect of azithromycin in treatment of COVID19
- Conditions
- SARS-COV2 ASSOCIATED INFECTION.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200415047092N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 110
Obtaining informed consent from patient or patient’s legal proxy for inclusion in this study.-
Patients must be over 18 years of age-
A documented positive PCR test for SARS-CoV-2 or one of the following criteria:1.Compelling clinical symptoms associated with a covid-19 infection; including: fever, dry cough and dyspnea2.A typically involvement of lungs observed in HRCT or Spiral CT scanning that can be strongly attributed to a covid-19 pneumonia3.
Patients that have developed known complications of a covid-19 infection such as acute respiratory distress syndrome (ARDS) or myocarditis.
pregnancy or nursing
Patients whose covid-10 infection has not been proven and have symptoms that can be attributed to either the common cold or influenza and/or have had a positive PCR test for influenza.
known allergy to chloroquine or hydroxylchloroquine
retinopathy
G6PD deficiency
prolonged QT interval
severe heart failure
Pacemaker implantation
cardiac arrhythmia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Peripheral capillary oxygen saturation. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: pulse oximeter.;Admission duration. Timepoint: From the beginning of the hospital visit to the discharge. Method of measurement: Questionnaire.;Fever. Timepoint: At the beginning of the visit and daily during admission. Method of measurement: Mercury thermometer.;Need to ICU admission. Timepoint: During admission. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method